| 1 |
Anstee QM, Reeves HL, Kotsiliti E，et al.From NASH to HCC：current concepts and future challenges [J]．Nat Rev Gastroenterol Hepatol，2019,16(7):411-428.
|
| 2 |
Argyrou C, Moris D, Vernadakis S．Hepatocellular carcinoma development in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.Is it going to be the "Plague" of the 21st century? A literature review focusing on pathogenesis，prevention and treatment [J]．J BUON，2017,22(1):6-20.
|
| 3 |
Eslam M, Newsome PN, Sarin SK，et al.A new definition for metabolic dysfunction-associated fatty liver disease：An international expert consensus statement [J]．J Hepatol，2020,73(1):202-209.
|
| 4 |
Degasperi E, Colombo M．Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease [J]．Lancet Gastroenterol Hepatol，2016,1(2):156-164.
|
| 5 |
Umano GR, Caprio S, Di Sessa A，et al.The rs626283 Variant in the MBOAT7 Gene is Associated with Insulin Resistance and Fatty Liver in Caucasian Obese Youth [J]．Am J Gastroenterol，2018,113(3):376-383.
|
| 6 |
Donati B, Dongiovanni P, Romeo S，et al.MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals[J]．Sci Rep，2017,7(1):4492.
|
| 7 |
Sutti S, Albano E．Adaptive immunity：an emerging player in the progression of NAFLD [J]．Nat Rev Gastroenterol Hepatol，2020,17(2):81-92.
|
| 8 |
Wu WKK, Zhang L, Chan MTV.Autophagy，NAFLD and NAFLD-Related HCC [J]．Adv Exp Med Biol，2018,1061:127-138.
|
| 9 |
Borrelli A, Bonelli P, Tuccillo FM，et al.Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma：Current and innovative therapeutic approaches [J]．Redox Biol，2018,15:467-479.
|
| 10 |
Chow MD, Lee YH, Guo GL.The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis [J]．Mol Aspects Med，2017,56:34-44.
|
| 11 |
Pennisi G, Celsa C, Giammanco A，et al.The Burden of Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease：Screening Issue and Future Perspectives [J]．Int J Mol Sci，2019,20(22):5613.
|
| 12 |
Hashimoto E, Yatsuji S, Tobari M，et al.Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis [J]．J Gastroenterol，2009,44 Suppl 19:89-95.
|
| 13 |
Kawamura Y, Arase Y, Ikeda K，et al.Large-scale long-term follow-up study of Japanese patients with non-alcoholic Fatty liver disease for the onset of hepatocellular carcinoma[J]．Am J Gastroenterol，2012,107(2):253-261.
|
| 14 |
Golabi P, Rhea L, Henry L, Younossi ZM.Hepatocellular carcinoma and non-alcoholic fatty liver disease [J]．Hepatol Int，2019,13(6):688-694.
|
| 15 |
Than NN, Ghazanfar A, Hodson J，et al.Comparing clinical presentations，treatments and outcomes of hepatocellular carcinoma due to hepatitis C and non-alcoholic fatty liver disease [J]．QJM，2017,110(2):73-81.
|
| 16 |
Tan H, Xu L, Liu X，et al.Hepatocellular carcinoma in nonalcoholic fatty liver disease mimicking benign hemangioma：two case reports and literature review [J]．Int J Clin Exp Pathol，2015,8(11):15350-15355.
|
| 17 |
Al-Sharhan F, Dohan A, Barat M，et al.MRI presentation of hepatocellular carcinoma in non-alcoholic steatohepatitis(NASH)[J]．Eur J Radiol，2019,119:108648.
|
| 18 |
Garcovich M, Faccia M, Meloni F，et al.Contrast-enhanced ultrasound patterns of hepatocellular adenoma：an Italian multicenter experience [J]．J Ultrasound，2019,22(2):157-165.
|
| 19 |
Hwang A, Shi C, Zhu E，et al.Supervised learning reveals circulating biomarker levels diagnostic of hepatocellular carcinoma in a clinically relevant model of non-alcoholic steatohepatitis；An OAD to NASH[J]．PLoS One，2018,13(6):e0198937.
|
| 20 |
Montagnana M, Danese E, Lippi G．Squamous cell carcinoma antigen in hepatocellular carcinoma：Ready for the prime time [J]? Clin Chim Acta，2015,445:161-166.
|
| 21 |
Gori M, Arciello M, Balsano C．MicroRNAs in nonalcoholic fatty liver disease：novel biomarkers and prognostic tools during the transition from steatosis to hepatocarcinoma[J]．Biomed Res Int，2014:741465.
|
| 22 |
Ye J, Li T S, Xu G，et al.JCAD Promotes Progression of Nonalcoholic Steatohepatitis to Liver Cancer by Inhibiting LATS2 Kinase Activity [J]．Cancer Res，2017,77(19):5287-5300.
|
| 23 |
Nakamura N, Hatano E, Iguchi K，et al.Elevated levels of circulating ITIH4 are associated with hepatocellular carcinoma with nonalcoholic fatty liver disease：from pig model to human study [J]．BMC Cancer，2019,19(1):621.
|
| 24 |
Best J, Bechmann L P, Sowa J P，et al.GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis[J]．Clin Gastroenterol Hepatol，2020,18(3):728-735.
|
| 25 |
朱风尚，杨长青，陈锡美．非酒精性脂肪性肝炎肝纤维化血清学无创诊断[J/CD]．中华消化病与影像杂志(电子版)，2014,3(6):38-41.
|
| 26 |
Yoneda M, Imajo K, Eguchi Y，et al.Noninvasive scoring systems in patients with nonalcoholic fatty liver disease with normal alanine aminotransferase levels [J]．J Gastroenterol，2013,48(9):1051-1060.
|
| 27 |
Hsu C Y, Lee Y H, Liu P H，et al.Decrypting cryptogenic hepatocellular carcinoma：clinical manifestations，prognostic factors and long-term survival by propensity score model [J]．PLoS One，2014,9(2):e89373.
|
| 28 |
Lim C, Bhangui P, Salloum C，et al.Impact of time to surgery in the outcome of patients with liver resection for BCLC 0-A stage hepatocellular carcinoma [J]．J Hepatol，2018,68(1):100-108.
|
| 29 |
寇昌华，韩锡林，庄惠杰，等．脂肪肝合并肝癌患者接受根治术后的临床疗效与安全性分析[J]．中国现代医生，2017,55(30):8-10.
|
| 30 |
Koh Y X, Tan H J, Liew Y X，et al.Liver Resection for Nonalcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma [J]．J Am Coll Surg，2019,229(5):467-478.
|
| 31 |
刘晓燕，李胜棉，杨俭.1293例原发性肝癌患者非酒精性脂肪性肝病的伴发率及预后特征[J]．临床肝胆病杂志，2010,26(6):641-643.
|
| 32 |
Xu W, Zhang X, Wu J L，et al.O-GlcNAc transferase promotes fatty liver-associated liver cancer through inducing palmitic acid and activating endoplasmic reticulum stress[J]．J Hepatol，2017,67(2):310-320.
|
| 33 |
Okada H, Takabatake R, Honda M，et al.Peretinoin，an acyclic retinoid，suppresses steatohepatitis and tumorigenesis by activating autophagy in mice fed an atherogenic high-fat diet [J]．Oncotarget，2017,8(25):39978-39993.
|
| 34 |
Bruix J, Qin S, Merle P，et al.Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment(RESORCE)：a randomised，double-blind，placebo-controlled，phase 3 trial[J]．Lancet，2017,389(10064):56-66.
|
| 35 |
Abou-Alfa GK, Meyer T, Cheng AL，et al.Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma [J]．N Engl J Med，2018,379(1):54-63.
|
| 36 |
El-Khoueiry A B, Sangro B, Yau T，et al.Nivolumab in patients with advanced hepatocellular carcinoma(CheckMate 040)：an open-label，non-comparative，phase 1/2 dose escalation and expansion trial [J]．Lancet，2017,389(10088):2492-2502.
|